同步放化疗联合艾迪辅助治疗对宫颈癌患者MMP-9、TIMP-1水平及炎症因子的影响

来源:用户上传      作者:葛燕露 朱迎萍 蒋军 庄雨龙

　　[摘要] 目的 ^察同步放化疗联合艾迪注射液治疗对宫颈癌的临床疗效、免疫功能及安全性研究。 方法 选取浙江省中医院2017年5月至2020年10月收治的98例住院患者，随机分为对照组与观察组，每组各49例。采用流式细胞仪测定治疗前后T细胞亚群（CD3+、CD4+、CD8+细胞率及CD4+/CD8+）变化。采用酶联免疫吸附法（ELISA）测定血清中基质金属蛋白酶（MMP-9）、组织蛋白酶抑制剂-1（TIMP-1）、肿瘤坏死因子-α（TNF-α）、白细胞介素4（IL-4）、白细胞介素10（IL-10）水平;并评价两组患者的近期临床疗效、生活质量及不良反应。 结果 近期疗效比较，观察组，总有效率为83.67%，高于对照组的75.51%（P<0.05）。外周血T细胞亚群，观察组CD8+水平明显高于对照组（P<0.05），CD4+/CD8+比例明显低于对照组（P<0.05）。两组患者生活质量评分，观察组治疗后的生活质量评分明显高于对照组（P<0.05）。观察组MMP-9、TIMP-1水平明显低于对照组（P<0.05）;观察组TNF-α、IL-4、IL-10水平明显低于对照组（P<0.05）。不良反应发生方面，观察组的骨髓抑制、肝肾功能损伤、乏力发生率明显低于对照组（P<0.05）。结论 艾迪注射液联合同步放化疗能显著提高中晚期宫颈癌患者的临床疗效，改善患者免疫功能，提高生活质量，降低不良反应，值得临床作为宫颈癌的综合治疗手段之一。
　　[关键词] 艾迪注射液;宫颈癌;免疫功能;有效率;生活质量评分
　　[中图分类号] R739.6 [文献标识码] B [文章编号] 1673-9701（2022）13-0009-04
　　[Abstract] Objective To observe the clinical efficacy， immune function and safety of concurrent chemoradiotherapy combined with Aidi injection on cervical cancer. Methods A total of 98 inpatients who were admitted to Zhejiang Hospital of Traditional Chinese Medicine from May 2017 to October 2020 were randomly divided into the control group and the observation group，each group had 49 cases.The changes of T cell subsets（CD3+，CD4+，CD8+ cell rates， and CD4+/CD8+） were determined by flow cytometry before and after treatment. The levels of matrix metalloproteinase（MMP-9）， tissue inhibitor of metalloproteinase-1 （TIMP-1）， tumor necrosis factor-α（TNF-α），interleukin-4 （IL-4） and interleukin-10 （IL-10） in serum were determined by the enzyme-linked immunosorbent assay （ELISA）. The short-term clinical efficacy， quality of life and adverse reactions were evaluated in the 2 groups. Results Comparison of the short-term clinical efficacy： the total effective rate in the observation group was 83.67% which was higher than 75.51% in the control group（P<0.05）. Peripheral blood T cell subsets： The CD8+ level in the observation group was significantly higher than that in the control group（P<0.05）， and the CD4+/CD8+ ratio in the observation group was significantly lower than that in the control group（P<0.05）. The quality of life score of the observation group was significantly higher than that of the control group after treatment （P<0.05）. The levels of MMP-9 and TIMP-1 in the observation group were significantly lower than those in the control group（P<0.05）.The levels of TNF-α，IL-4 and IL-10 in the observation group were significantly lower than those in the control group（P<0.05）.In terms of the occurrence of adverse reactions， the incidences of bone marrow suppression， liver and kidney function injury and fatigue in the observation group were significantly lower than those in the control group（P<0.05）. Conclusion The Aidi injection combined with concurrent chemoradiotherapy can significantly improve the clinical efficacy of patients with middle and advanced cervical cancer，improve the immune function of patients，improve the quality of life，reduce adverse reactions，and is worthy of clinical recommendation as one of the comprehensive treatment methods for cervical cancer.

nlc202206161128

转载注明来源:https://www.xzbu.com/6/view-15433760.htm